{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:20:00Z","timestamp":1758050400323,"version":"3.44.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bulcan.2020.07.005","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T11:25:53Z","timestamp":1601033153000},"page":"1171-1185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bouff\u00e9es de chaleur et cancer du sein avec r\u00e9cepteurs hormonaux positifs\u00a0: m\u00e9canismes et prise en charge"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4599-4729","authenticated-orcid":false,"given":"Iphig\u00e9nie","family":"Cavadias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Rouzier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Lerebours","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"H\u00e9quet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"unstructured":"Institut national du cancer. Le cancer du sein en chiffres. [Consult\u00e9 le 12\u00a0janvier 2020. Disponible sur\u00a0: https:\/\/www.e-cancer.fr\/Professionnels-de-sante\/Les-chiffres-du-cancer-en-France\/Epidemiologie-des-cancers\/Les-cancers-les-plus-frequents\/Cancer-du-sein, derni\u00e8re mise \u00e0 jour le 03\/07\/2019]","key":"10.1016\/j.bulcan.2020.07.005_bib0345"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0350","doi-asserted-by":"crossref","first-page":"e1918160","DOI":"10.1001\/jamanetworkopen.2019.18160","article-title":"Clinicopathological characteristics and breast cancer-specific survival of patients with single hormone receptor-positive breast cancer","volume":"3","author":"Li","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0355","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1210\/jc.2017-01138","article-title":"Managing menopausal symptoms and associated clinical issues in breast cancer survivors","volume":"102","author":"Santen","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0360","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/ajhb.1077","article-title":"Physiology of hot flashes","volume":"13","author":"Freedman","year":"2001","journal-title":"Am J Hum Biol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0365","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.fertnstert.2014.08.016","article-title":"Magnitude of the impact of hot flashes on sleep in perimenopausal women","volume":"102","author":"de Zambotti","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0370","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1001\/jama.1981.03310420031025","article-title":"Association of waking episodes with menopausal hot flushes","volume":"245","author":"Erlik","year":"1981","journal-title":"JAMA"},{"issue":"6094","key":"10.1016\/j.bulcan.2020.07.005_bib0375","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/bmj.2.6094.1062","article-title":"Hot flushes after hypophysectomy","volume":"2","author":"Mulley","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0380","first-page":"2354","article-title":"Core body temperature and circadian rhythm of hot flashes in menopausal women","volume":"80","author":"Freedman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0385","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0002-9378(99)70437-0","article-title":"Reduced thermoregulatory null zone in postmenopausal women with hot flashes","volume":"181","author":"Freedman","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0390","first-page":"1158","article-title":"The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women","volume":"32","author":"Blum","year":"1996","journal-title":"Isr J Med Sci"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0395","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1210\/en.2018-00389","article-title":"KNDy cells revisited","volume":"159","author":"Moore","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0400","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1210\/me.2015-1189","article-title":"Divergent regulation of ER and Kiss genes by 17\u03b2-Estradiol in hypothalamic ARC versus AVPV models","volume":"30","author":"Treen","year":"2016","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0405","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.yfrne.2013.07.003","article-title":"Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes","volume":"34","author":"Rance","year":"2013","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0410","doi-asserted-by":"crossref","first-page":"8466","DOI":"10.1038\/srep08466","article-title":"Neurokinin B administration induces hot flushes in women","volume":"5","author":"Jayasena","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0415","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(15)00049-2","article-title":"Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3\u00a0randomised trials","volume":"16","author":"Bernhard","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0420","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0425","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0430","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0140-6736(11)61823-0","article-title":"The 2011\u00a0EBCTCG polychemotherapy overview","volume":"379","author":"Palmieri","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0435","doi-asserted-by":"crossref","first-page":"e88238","DOI":"10.1371\/journal.pone.0088238","article-title":"Extended adjuvant tamoxifen for early breast cancer: a meta-analysis","volume":"9","author":"Al-Mubarak","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0440","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0022-3565(24)38923-2","article-title":"Molecular mechanisms of selective estrogen receptor modulator (SERM) action","volume":"295","author":"Dutertre","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0445","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1\u00a0Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0450","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12338","article-title":"Hypothalamic effects of tamoxifen on oestrogen regulation of luteinising hormone and prolactin secretion in female rats","volume":"28","author":"Aquino","year":"2016","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0455","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0460","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMoa0810818","article-title":"Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer","volume":"361","author":"BIG 1-98\u00a0Collaborative Group","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0465","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","article-title":"Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3\u00a0trial","volume":"377","author":"van de Velde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0470","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0475","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0480","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","article-title":"Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group","volume":"26","author":"Paridaens","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0485","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500mg versus anastrozole 1mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3\u00a0trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0490","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","article-title":"Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769\u00a0early-stage breast cancer patients","volume":"28","author":"Hershman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0495","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0500","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0505","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1200\/JCO.2003.04.024","article-title":"Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study","volume":"21","author":"Nystedt","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0510","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/JCO.2015.64.8675","article-title":"Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial","volume":"34","author":"Ribi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0515","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdz298","article-title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis","volume":"30","author":"Ferreira","year":"2019","journal-title":"Ann Oncol"},{"unstructured":"Hot flashes & breast cancer survivors, menopause relief. The North American Menopause Society, NAMS. [Consult\u00e9 le 20\u00a0f\u00e9vrier 2020. Disponible sur\u00a0: http:\/\/www.menopause.org\/for-women\/menopauseflashes\/menopause-symptoms-and-treatments\/breast-cancer-survivors-hot-flash-treatments], copyright 2020","key":"10.1016\/j.bulcan.2020.07.005_bib0520"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0525","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-014-2963-1","article-title":"Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22","volume":"145","author":"Baxter","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0530","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10549-018-4876-x","article-title":"CYP2D6\u00a0genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy","volume":"171","author":"Jansen","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0535","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.breast.2019.05.009","article-title":"Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?","volume":"46","author":"Lee","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0540","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia","volume":"37","author":"DeCensi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0545","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2005.06.064","article-title":"Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen","volume":"23","author":"Rouanet","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0550","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0555","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ctrv.2016.11.012","article-title":"Management of hot flashes in women with breast cancer receiving ovarian function suppression","volume":"52","author":"Leon-Ferre","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0560","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(00)03403-6","article-title":"Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial","volume":"356","author":"Loprinzi","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0565","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.AOG.0000147840.06947.46","article-title":"Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial","volume":"105","author":"Evans","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0570","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000297371.89129.b3","article-title":"Study 315\u00a0investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial","volume":"111","author":"Speroff","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0575","article-title":"A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause","volume":"200","author":"Archer","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0580","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2009.26.6379","article-title":"Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9","volume":"28","author":"Barton","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0585","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.2010.2016","article-title":"Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial","volume":"305","author":"Freeman","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0590","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1001\/jama.289.21.2827","article-title":"Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial","volume":"289","author":"Stearns","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0595","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1200\/JCO.2005.10.081","article-title":"Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial","volume":"23","author":"Stearns","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0600","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.gme.0000196595.82452.ca","article-title":"Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population","volume":"13","author":"Gordon","year":"2006","journal-title":"Menopause"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0605","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/01.AOG.0000258278.73505.fa","article-title":"Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial","volume":"109","author":"Grady","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0610","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1075-122X.2006.00218.x","article-title":"Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen","volume":"12","author":"Kimmick","year":"2006","journal-title":"Breast J"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0615","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1200\/JCO.2002.20.6.1578","article-title":"Phase III evaluation of fluoxetine for treatment of hot flashes","volume":"20","author":"Loprinzi","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0620","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1389200023338017","article-title":"Selective serotonin reuptake inhibitors and cytochrome P-450\u00a0mediated drug-drug interactions: an update","volume":"3","author":"Hemeryck","year":"2002","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0625","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","article-title":"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine","volume":"95","author":"Stearns","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0630","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv337","article-title":"Tamoxifen and antidepressant drug interaction in a cohort of 16,887\u00a0breast cancer survivors","volume":"108","author":"Haque","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0635","first-page":"337","article-title":"Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial","volume":"101","author":"Guttuso","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0640","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0140-6736(05)67215-7","article-title":"Gabapentin for hot flashes in 420\u00a0women with breast cancer: a randomised double-blind placebo-controlled trial","volume":"366","author":"Pandya","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0645","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1200\/JCO.2009.24.5647","article-title":"Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1","volume":"28","author":"Loprinzi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0650","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.1994.12.1.155","article-title":"Transdermal clonidine for ameliorating tamoxifen-induced hot flashes","volume":"12","author":"Goldberg","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0655","doi-asserted-by":"crossref","first-page":"788","DOI":"10.7326\/0003-4819-132-10-200005160-00004","article-title":"Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study","volume":"132","author":"Pandya","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0660","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(17)30823-1","article-title":"Neurokinin 3\u00a0receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"389","author":"Prague","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0665","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/GME.0000000000000773","article-title":"Extended-release oxybutynin therapy for VMS Study Group. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial","volume":"23","author":"Simon","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0670","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1200\/JCO.2010.33.1298","article-title":"Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial","volume":"29","author":"Boekhout","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0675","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1200\/JCO.2010.29.9230","article-title":"Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors","volume":"28","author":"Bordeleau","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.07.005_bib0680","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.AOG.0000222383.43913.ed","article-title":"Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial","volume":"108","author":"Reddy","year":"2006","journal-title":"Obstet Gynecol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120303489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120303489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:33:10Z","timestamp":1757791990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455120303489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0007455120303489"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.07.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bouff\u00e9es de chaleur et cancer du sein avec r\u00e9cepteurs hormonaux positifs\u00a0: m\u00e9canismes et prise en charge","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}